UBS Starts Hospira (HSP) at Sell; Itching to Get Involved, But Still Early

UBS initiates coverage on Hospira (NYSE: HSP) with a Sell. PT $25.00.

UBS analyst says, "HSP looks attractive at its current 52-week low levels, given its strong medium/long-term growth prospects. But we think it is too early to build a position in the name, as consensus for 2012/2013 seems still high and manufacturing issues will probably worsen before improving. We plan to revisit our view in 2012 as we gain visibility into EPS growth...We are $0.35-0.40 below consensus for both years as we believe recovery from manufacturing issues could be slow and management will invest in R&D in line with its previous guidance."

For an analyst ratings summary and ratings history on Hospira click here. For more ratings news on Hospira click here.

Shares of Hospira closed at $28.21 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• BofA Securities Starts Kanzhun Ltd. (BZ) at Neutral
• ThinkEquity Starts Deep Isolation Nuclear (DBHL) at Buy
• Wedbush Starts Immunic Inc. (IMUX) at Outperform